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Acetaminophen-cysteine adducts during
therapeutic dosing and following overdose
Kennon J Heard1,2*, Jody L Green1,3, Laura P James4, Bryan S Judge5, Liza Zolot1, Sean Rhyee6, Richard C Dart1,2
Abstract
Background: Acetaminophen-cysteine adducts (APAP-CYS) are a specific biomarker of acetaminophen exposure.
APAP-CYS concentrations have been described in the setting of acute overdose, and a concentration >1.1 nmol/ml
has been suggested as a marker of hepatic injury from acetaminophen overdose in patients with an ALT >1000 IU/
L. However, the concentrations of APAP-CYS during therapeutic dosing, in cases of acetaminophen toxicity from
repeated dosing and in cases of hepatic injury from non-acetaminophen hepatotoxins have not been well
characterized. The objective of this study is to describe APAP-CYS concentrations in these clinical settings as well
as to further characterize the concentrations observed following acetaminophen overdose.
Methods: Samples were collected during three clinical trials in which subjects received 4 g/day of acetaminophen
and during an observational study of acetaminophen overdose patients. Trial 1 consisted of non-drinkers who
received APAP for 10 days, Trial 2 consisted of moderate drinkers dosed for 10 days and Trial 3 included subjects
who chronically abuse alcohol dosed for 5 days. Patients in the observational study were categorized by type of
acetaminophen exposure (single or repeated). Serum APAP-CYS was measured using high pressure liquid
chromatography with electrochemical detection.
Results: Trial 1 included 144 samples from 24 subjects; Trial 2 included 182 samples from 91 subjects and Trial 3
included 200 samples from 40 subjects. In addition, we collected samples from 19 subjects with acute
acetaminophen ingestion, 7 subjects with repeated acetaminophen exposure and 4 subjects who ingested another
hepatotoxin. The mean (SD) peak APAP-CYS concentrations for the Trials were: Trial 1- 0.4 (0.20) nmol/ml, Trial 2-
0.1 (0.09) nmol/ml and Trial 3- 0.3 (0.12) nmol/ml. APAP-CYS concentrations varied substantially among the patients
with acetaminophen toxicity (0.10 to 27.3 nmol/ml). No subject had detectable APAP-CYS following exposure to a
non-acetaminophen hepatotoxin.
Conclusions: Lower concentrations of APAP-CYS are detectable after exposure to therapeutic doses of
acetaminophen and higher concentrations are detected after acute acetaminophen overdose and in patients with
acetaminophen toxicity following repeated exposure.
Background
Acetaminophen toxicity is a major cause of acute liver
failure in the United States. While many cases have a
clear history of acetaminophen exposure, there are a
substantial number of cases in which the cause of liver
injury is not clear. As serum acetaminophen concentra-
tions may be undetectable by the time the patient has
acute liver failure, there is a need for a biomarker with a
longer detection time.
The metabolism of acetaminophen by CYP2E1 forms
N-acetyl-p-benzoquinone imine (NAPQI), a reactive
metabolite that binds to cysteine residues in cellular
proteins and forms acetaminophen protein adducts,
herein referred to acetaminophen-cysteine (APAP-CYS)
[1]. Previous experimental work has shown that APAP-
CYS is formed within hepatocytes and released into the
circulation following cell necrosis in the setting of acute
acetaminophen toxicity [2,3]. This product is detectable
in serum for several days following acute overdose, and
it has been proposed that detection of APAP-CYS is
diagnostic of acetaminophen toxicity [4]. The majority
of the studies measuring APAP-CYS have included
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patients with known or suspected acute overdose of
acetaminophen [4-7].
While studies of patients with acetaminophen-induced
liver injury can determine the sensitivity of the assay, the
performance of the assay cannot be studied solely in this
population. For a diagnostic study to be valid, the assay
should be evaluated in patients who have similar diseases
to the diagnosis of interest. Therefore, in this study, the
assay was tested in other patient groups including
patients with liver injury from other causes, patients tak-
ing therapeutic doses of acetaminophen and patients
with liver injury following repeated ingestion of supra-
therapeutic doses of acetaminophen. The objective of
this study is to describe the serum concentrations of
APAP-CYS measured under five conditions: 1) during
therapeutic dosing, 2) in patients with suspected acetami-
nophen toxicity from repeated overdosing, 3) following
acute acetaminophen overdose with early acetylcysteine
treatment, 4) following acute acetaminophen overdose
with delayed acetylcysteine treatment and 5) following
ingestion of non-acetaminophen hepatotoxins.
Methods
This report describes the analysis of samples collected in
two settings: 1) during three clinical trials that included
an acetaminophen treatment arm and 2) an observational
study of patients with an overdose of acetaminophen or
another hepatotoxin. The three clinical trials was sepa-
rately reviewed and approved by the Colorado Multiple
Institutional Review Board. Trial 3 was also approved by
the Center For Addition and Mental Health Research
Ethics Board. The observational study was approved by
the Colorado Multiple Institutional Review Board and
the Spectrum Health Research and Human Rights Com-
mittee. All subjects provided informed consent for inclu-
sion in the trials and in the observational study.
Study methods for clinical trials
The populations, duration of dosing and days of sam-
pling for all trials are shown in Table 1. The clinical
trials were performed to evaluate the effect of acetami-
nophen on serum transaminase activity. In all clinical
trials, healthy adult subjects older than 21 years were
administered the maximum daily dose of acetamino-
phen (4 g/day) or placebo (only Trials 2 and 3 had a
placebo arm). The study subjects were non-drinkers
(Trial 1-Registration number NCT 00616018) [8],
moderate drinkers (Trial 2 Registration number NCT
004000621) [9] and subjects who chronically abuse
alcohol (Trial 3- Registration number NCT 00427206)
[10]. For Trial 2, moderate drinking was defined as 1-3
alcoholic beverages per day. For Trial 3, subjects who
chronically abuse alcohol were identified at an inpati-
ent detoxification facility; the average duration of their
current drinking binge was longer than 1 month. Sub-
jects in Trials 1 and 3 could not consume ethanol dur-
ing the study; subjects in Trial 2 were instructed to
continue their usual drinking pattern during the study
(an average of 1-3 drinks/day). The first acetamino-
phen or placebo dose was administered on study day 1
in all trials.
Study methods for observational study
In the observational study, patients were enrolled by two
medical toxicology services evaluating patients for
known or suspected acetaminophen overdose. The fol-
lowing patients were eligible for enrollment: 1) patients
following acute acetaminophen ingestion (defined as a
single ingestion or multiple ingestions occurring within
an 8 hour period), 2) patients with repeated acetamino-
phen ingestions (defined as multiple ingestions over a
period of greater than 8 hours); 3) patients that may
have ingested a product that may produce hepatotoxicity
(other than acetaminophen). A trained investigator col-
lected a structured data set for each patient subject
including demographics, time course of ingestion,
Table 1 Characteristics and peak recorded serum APAP-
CYS concentrations for subjects administered 4 g/day of
acetaminophen during three clinical trials
Study
Trial 1 Trial 2 Trial 3
Subjects Non-drinkers Moderate
drinkers
Alcoholics
Duration of dosing 10 d 10 d 5 d
Days of sampling 0, 4, 7, 9,
11,14
0,11 0, 2, 4, 6,7
n 24 91 APAP
47 placebo
40 APAP/
7 placebo
Median age (range) years 34.5 (23 to 63) 30 (21 to 64) 46 (33 to 66)
Male 7 (29%) 47 (52%) 39 (98%)
ALT
Baseline ALT
Median (Range) IU/L
24 (14 to 45) 19 (11 to 49) 29 (10 to
178)
Peak ALT
Median (Range) IU/L
45 (19 to 136) 25 (14 to
128)
47.5 (8 to
238)
ALT >ULN during
study n (%)
14 (58%) 17 (19%) 24 (60%)
Peak Serum APAP-CYS
Mean (SD) nmol/L 0.4 (0.20) 0.1 (0.09)* 0.3 (0.12)
Range nmol/L 0.1 to 1.0 0.0 to 0.5 0.1 to 0.8
Trial 1 included non-drinkers treated for 10 days, Trial 2 included moderate
drinkers treated for 10 days and Trial 3 included alcoholic subjects treated for
five days. APAP-CYS-Acetaminophen-cysteine adducts, ALT-alanine
aminotransferase, ULN-upper limits of normal for the test. SD-standard
deviation.
*p < 0.001 vs Trial 1 and 3.
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co-ingestions (including ethanol), medical history
(including history of alcohol abuse and liver disease)
and clinical course (including time of acetylcysteine
treatment relative to the overdose, laboratory variables
and outcome). Samples for APAP-CYS quantification
were collected during routine blood draws, and there-
fore sample collection was not systematically timed. In
this report we refer to the highest recorded determina-
tion as the peak value, but we recognize that our non-
systematic sampling scheme may miss the true peak
values.
The patients in the overdose cohort were stratified
into the following four groups: 1) Acute acetaminophen
ingestion who received acetylcysteine within 8 hours
(acute early treatment), 2) acute acetaminophen inges-
tion who received acetylcysteine after 8 hours (acute late
treatment), 3) repeated acetaminophen ingestion and 4)
ingestion of a hepatotoxin without acetaminophen.
Sample Preparation, APAP-CYS Protein Adduct Assay
Serum samples were frozen at each institution and
stored at -80°C until analysis. Samples were analyzed
using a previously described method [6]. The samples
were processed with gel filtration, protein digestion and
the resulting APAP-CYS concentration was determined
by high pressure liquid chromatography using electro-
chemical detection. The limit of detection of the assay is
0.03 uM (micromolar) based on the lowest quality con-
trol concentration measured with a CV of within 15%.
The final concentrations are reported as nmol of APAP-
CYS/ml of serum to be consistent with previous
publications.
Analysis plan
For both the trials and the observational study, categori-
cal variables are described as percentages with 95%
exact binomial confidence intervals. Continuous vari-
ables that were non-skewed are reported using means
with standard deviations while continuous variables with
skewed distributions are described using medians with
inter-quartile ranges. The mean peak adduct concentra-
tions for the three therapeutic trials were compared
using ANOVA with a protected Fisher’s Least Signifi-
cant Difference to adjust for multiple comparisons in
post hoc tests. An overall, 2-sided p-value <0.05 was
considered significant. The relationship of peak APAP-
CYS concentrations to peak ALT for each trial was
evaluated with Spearman’s rho. If the 95% confidence
intervals for rho included zero, we considered there to
be no significant relationship between peak recorded
ALT and peak recorded APAP-CYS. Calculations were
performed using SAS version 9.2 (Carey, NC) and corre-
lations were performed using Prism 5.0 (GraphPad Soft-
ware, San Diego CA).
Results
Clinical trials
There were 144 samples from 24 subjects in Trial 1, 276
samples from 91 APAP and 47 placebo subjects in Trial 2,
and 200 samples from 40 APAP and 7 placebo subjects in
Trial 3. The demographics and peak recorded APAP-CYS
concentrations in trial subjects are shown in Table 1.
At baseline, no subjects in Trial 1, 6 subjects in Trial 2
(2 acetaminophen, 4 placebo) and 5 subjects (1 placebo,
4 APAP) in Trial 3 had detectable APAP-CYS concentra-
tions. Of these 11 APAP-CYS baseline positive subjects,
4 reported acetaminophen use in the 4 days preceding
the study and had detectable APAP serum concentra-
tions at baseline, 3 reported use in the 4 days preceding
the study but did not have a detectable serum APAP con-
centration at baseline, 1 subject denied acetaminophen
use, but had a detectable APAP concentration at baseline
and 3 subjects denied acetaminophen ingestion and had
no detectable acetaminophen at baseline.
All acetaminophen-treated subjects (n = 115) in the
Trials 1 and 3 had detectable APAP-CYS in one or
more samples. Eighty five of 91 APAP-treated subjects
in Trial 2 had detectable serum concentrations of
APAP-CYS on day 11 of the trial. Thus, overall, APAP-
CYS was detected in the vast majority of samples
obtained from the APAP-treated arms of the 3 trials.
The mean peak recorded adduct concentrations in Trial
2 were lower than concentrations measured in Trials 1
and 3 (p < 0.001, values shown in Table 1). However,
there was substantial overlap of individual subject values
between the trials and these differences are unlikely to
be of clinical significance (Figure 1).
Two placebo treated subjects in Trial 2 and 1 placebo
treated subject in Trial 3 had detectable APAP-CYS at
Figure 1 Serum APAP-CYS concentrations for subjects in three
trials. Subjects received 4 g/day of acetaminophen for 10 days
(Trials 1 and 2) or 5 days (trial 3) starting at day 1. Bars represent
the 10-90th percentile for each study and values outside that range
are shown as ‘•’.
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the end of the study. All of these subjects had detectable
APAP-CYS concentrations (0.03, 0.16, 0.17 nmol/ml)
at baseline and the final concentrations (0.004, 0.06,
0.09 nmol/ml respectively) were lower than the baseline
concentrations.
Mean APAP-CYS concentrations tended to increase
during the dosing period of each study (Figure 1). In
Trial 1, samples were collected 1 and 4 days after the
final acetaminophen dose and in Trial 3 samples were
collected 1 and 3 days after the final acetaminophen
dose. In both of these trials, the APAP-CYS concentra-
tions 1 day after dosing was stopped were similar to the
concentrations measured during dosing, and samples
obtained 3 or 4 days after stopping acetaminophen were
lower than those observed on dosing (Figure 1).
Peak recorded APAP-CYS concentrations and peak
recorded ALT for all subjects receiving therapeutic
doses are shown in Figure 2. Please note that peak
recorded values of APAP-CYS and ALT did not neces-
sarily occur at the same time point so the values
reported in Figure 2. The Spearman’s rho correlation
(with 95% CI) of the relationship between ALT and
APAP-CYS for all trials was not significant: Trial 1 0.40
(-0.37 to 0.44); Trial 2 0.23 (-0.02 to 0.41) and Trial
3 0.14 (-0.18 to 0.43).
Observational study
Thirty five patients were enrolled in the observational
study; this included 31 acetaminophen overdoses and 4
subjects who had ingested another hepatotoxin. No
serum samples were obtained for APAP-CYS analysis in
4 patients (all acetaminophen), so these patients were
excluded. Note that the subject numbers shown in the
tables and figures are non-consecutive because packets
were pre-numbered; missing numbers reflect unused
packets rather than exclude subjects. Among the
remaining patients, the types of acetaminophen
ingestion were: 12 acute early treatments (within
8 hours of exposure), 7 acute late treatments (more
than 8 hours post exposure), 7 repeated ingestions and
1 unknown. This analysis included a total of 82 samples
for APAP-CYS measurement. The number of samples
for each patient ranged from 1 to 5. All of the patients
who reported ingesting acetaminophen had detectable
serum APAP-CYS and none of the 4 patients who
reported ingesting hepatotoxins without acetaminophen
had APAP-CYS detected (Table 2). Figures 3, 4, and 5
show the time course of serum APAP-CYS concentra-
tions and ALT activity for selected patients in the aceta-
minophen overdose group who had three or more
measurements. The figures are segregated by time
to treatment with NAC (early, Figure 3), >8 hour
(Figure 4), and by patients with supratherapeutic aceta-
minophen ingestions (Figure 5).
As the values for both ALT and APAP-CYS were
highly skewed in the overdose and toxicity patients, the
values were log transformed for analysis. A plot of the
log of adduct concentrations versus log of ALT is shown
in Figures 6. Please note that peak recorded values of
APAP-CYS and ALT did not necessarily occur at the
same time point so the values reported in Figure 6. There
was a modest Spearman correlation between the peak
recorded adducts and peak recorded ALT (rho = 0.68,
95% CI 0.36 to 0.85).
Discussion
Our study results demonstrate that low concentrations
of APAP-CYS are detectable in serum following thera-
peutic dosing with acetaminophen in the vast majority
of subjects. The peak recorded APAP-CYS concentra-
tions are higher in non-drinkers and abstaining subjects
who chronically abuse alcohol than in moderate drin-
kers, but the differences were small. The APAP-CYS
concentrations following acetaminophen overdose varied
widely. Serum APAP-CYS concentrations in patients
with hepatic injury following acetaminophen overdose
were generally much higher than those observed during
therapeutic dosing. However, three overdose subjects
(Subjects SH-05, SH-06, DH-06 in Figure 5) with nor-
mal serum ALT activity or minimal ALT elevation (due
to early treatment with N-acetylcysteine or late sampling
during resolution of injury) had APAP-CYS concentra-
tions that were of the same order of magnitude as those
observed with therapeutic dosing.
A previous report showed measureable APAP-CYS
concentrations with therapeutic dosing [11]. Based on
earlier published data in animal models, and early in the
development of this assay, APAP-CYS formation was
thought to occur only after acetaminophen overdose
with hepatic injury [12,13]. However, as the sensitivity
Figure 2 Peak APAP-CYS concentration by peak ALT during
three trials where subjects were administered 4 g/day of
acetaminophen.
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of the assay has improved [6,14], it is clear that that
APAP-CYS formation occurs in the setting of low dose
exposure associated without ALT activity [11].
An unexpected finding was that APAP-CYS concen-
trations were lower at study day 11 in Trial 2 than the
end of study samples collected for the subjects in Trial
1 (study day 11) and Trial 3 (study day 7). No adducts
were detected in six of the 91 APAP dosed patients on
study day 11 in Trial 2. Slight differences in the sam-
pling scheme among these three studies make direct
comparisons difficult. It is possible that these differences
are due to variations in sample timing, handling or pro-
cessing or non-compliance with study medication. How-
ever, overall compliance with dosing in Trial 2 was
Table 2 Demographics and clinical characteristics of patients enrolled following acute overdose, repeated overdose or
after ingestion of a non-acetaminophen hepatotoxin
Patient
number
Age/
Sex
Peak ALT IU/
L
Case description
Acute acetaminophen treated within 8 hours of ingestion
D-01 26 F 37 40 unknown strength tabs. 4.5 hr [APAP] 230 mcg/ml. 6.5 hrs to NAC.
D-02 20 F 18 20 g. 2.5 hr [APAP] 262 mcg/ml. 5 hr to NAC.
D-04 35 F 26 10-13 g. 6 hr [APAP] 177 mcg/ml. 7 hr to NAC.
D-06 20 F 17 Approx 30 tabs unknown strength. 4 hr [APAP] 319 mcg/ml. 6 hr to NAC.
SH-03 55 F 16 10.4 g. 4 hr [APAP] 184 mcg/ml. 6 hr to NAC.
SH-04 22 M 9903 25 g. 5 hr [APAP] 221 mcg/ml. 7 hr to NAC.
SH-05 38 F 57 39 g. 13 hr [APAP] 296 mcg/ml. 3.5 hr to NAC.
SH-06 16 F 14 “3 handfuls” of unknown product. 4 hr [APAP] 293 mcg/ml. 5.5 Hr to NAC.
SH-07 24 M 27 13-16.5 g. 6 hr [APAP] 235 mcg/ml. 8 hr to NAC.
SH-12 42 M 30 Unknown amount. 4 hr [APAP] 215 mcg/ml. 7 hr to NAC.
UCH-05 27 F 1729 48 gm. 1 hr [APAP] 557 mcg/ml. 5.5 hr to NAC.
UCH-06 51 F 22 19.5-53 g. 3 hr [APAP] 467 mcg/ml. 5 hr to NAC.
Acute acetaminophen treated more than 8 hours post ingestion
D-05 25 F 18 Unknown amount. 8 hr [APAP] 373 mcg/ml. 9 hr to NAC.
D-07 38 M 8880 7 g. 41 hr [APAP] 9 mcg/ml. 49 hr to NAC. Hep C.
D-08 37 F 1999 5 g × 2 8 hrs apart. 12 hr (from first ingestion) [APAP] 121 mcg/ml. 13 hr to NAC.
SH-08 37 F 1362 13-16 g. 10 hr [APAP] 89 mcg/ml. Time to NAC 15 hr.
UCH-01 52 F 457 15-25 g. 24 hr [APAP] 10 mcg/ml. Time to NAC 26 hr.
UCH-07 40 F 2083 Unknown amt. 27 hr [APAP] 336 mcg/ml. Time to NAC 28 hr.
UCH-14 41 F 4372 30 g. 36 hr [APAP] 5.6 mcg/ml. Time to NAC 36 hr.
Repeated acetaminophen ingestion
D-00 27 M 741 Approximately 10 g/day for 4 d for dental pain. Presenting [APAP] 0 mcg/ml.
D-18 17 M 229 Approximately 4 g/day for 2 d then 8 g/day for 1 day for prevertebral abscess. Presenting [APAP]
20 mcg/ml.
D-19 44 F 2862 4-6 g/day for 4 days then 25-50 g OD. 60 hr [APAP] 0 mcg/ml. NAC 14.5 hr post OD.
UCH-03 28 F 3189 2-3 tabs unknown str every 2-4 hrs for 7 d. Presenting [APAP] 16 mcg/ml.
UCH-08 29 F 2099 Approx 12 gm over 14 hrs. Presenting [APAP] 0 mcg/ml.
UCH-09 38 F 284 21 g over 5 d. Presenting [APAP] 0 mcg/ml. CMV hepatitis on liver biopsy.
UCH-11 24 M 7979 5-7.5 g/day for 4 d. presenting [APAP] 0 mcg/ml.
Acetaminophen ingestion-not able to determine time course
UCH-15 29 F 131 Unknown amt over several hours. Presenting [APAP] 36 mcg/ml. Polypharmacy OD.
Ingestion of other hepatotoxins
D-16 12 M 2346 Isoniazd-induced liver injury during therapeutic use.
SH-01 47 M 174 1500 mg of tramadol. Alcoholic
SH-02 24 M 18 9.5 g of valproic acid.
SH-09 18 F 18 8 g phenytoin.
[APAP]- serum acetaminophen concentration, NAC- acetylcysteine, ALT- alanine aminotransferase.
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similar to the compliance reported for Trial 1 (<1% of
doses missed for both studies) and the six Trial 2 sub-
jects with undetectable adduct concentrations did not
report any missed doses. An alternative hypothesis is
that ethanol exposure may have altered adduct forma-
tion. As ethanol is a known inhibitor of CYP 2E1, the
enzyme primarily responsible for the formation of
NAPQI with therapeutic doses of acetaminophen, it is
possible that ethanol blocked NAPQI formation in the
group allowed to consume ethanol during the study
while the other two groups were not allowed to drink
and thus had more metabolism of acetaminophen via
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Figure 3 Serum APAP-CYS concentrations and ALT activity for seven patients who received acetylcysteine treatment within 8 hours of
their acute acetaminophen overdose. Clinical characteristics of the cases are shown in Table 2. Note that the scale of the axes are different for
subject SH-04 to reflect in the range of values for this subject.
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Figure 4 Serum APAP-CYS concentrations and ALT activity for three patients who received acetylcysteine treatment more than 8
hours after their acute acetaminophen overdose. Clinical characteristics of the cases are shown in Table 2. Note that the scale of the axes
are not the same for all subjects to reflect the differences in the range of values.
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Figure 5 Serum APAP-CYS concentrations and ALT activity for three patients who were treated with acetylcysteine for hepatic injury
following repeated supratherapeutic ingestion of acetaminophen. Clinical characteristics of the cases are shown in Table 2. Note that the
scale of the axes are not the same for all subjects to reflect the differences in the range of values.
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CYP 2E1 to NAPQI This mechanism could be further
investigated in future large prospective study that com-
pared different ethanol exposures concurrent with
APAP exposure and a single sampling scheme.
As no patients who ingested non-acetaminophen hepa-
totoxins had detectable serum APAP-CYS, our findings
support prior publications suggesting that the serum
APAP-CYS is specific for APAP exposure in overdose
patients [4,12]. Our findings are limited as we only had 4
patients non-acetaminophen patients. In addition, most
patients who received early treatment with NAC (Figure
3), had lower adduct concentrations than those that had
late treatment with NAC (Figure 4). An exception to this
generalization is patient SH-04 (Figure 3). This patient
had a low ALT and APAP-CYS concentration at presenta-
tion but went on to develop a marked ALT elevation and
high APAP-CYS concentration consistent with acetamino-
phen-induced liver injury. The placebo subjects who had
APAP-CYS detected at the end of treatment during the
therapeutic trials had measurable concentrations prior to
starting the trial and the concentration decreased during
the trial. We believe this finding to be consistent with
acetaminophen ingestion prior to the trial.
A serum APAP-CYS concentration greater than
1.1 nmol/ml has a sensitivity of 97% for identification of
patients with hepatotoxicity (defined as an ALT values
of >1000 IU/L) when applied to a cohort of patients
with acetaminophen overdose [6]. While the mean con-
centrations in our three therapeutic trials were well
below this threshold, one patient in Trial 1 had a peak
recorded APAP-CYS concentration of 1.0 nmol/ml and
another patient in Trial 3 had a concentration of
0.8 nmol/ml. Further studies are required to determine
if the high sensitivity of this assay threshold is main-
tained when applied to populations other than acetami-
nophen overdoses (i.e. therapeutic dosing).
During therapeutic trials, APAP-CYS concentrations
increased during the dosing period. It is unknown
whether a plateau occurs at some point or whether con-
centrations continue to rise as long as acetaminophen is
consumed. In overdose cases, APAP-CYS concentrations
generally decreased following the peak in late presenters
and patients with repeated ingestions; the rate of decline
closely follows that of ALT and AST. This is consistent
with previous reports [6]. The concentrations showed a
less consistent decrease in the acute presentations who
were treated early.
We found no relationship between APAP-CYS con-
centrations and serum ALT activity (a commonly used
marker of liver injury) in the three trials of therapeutic
exposure. One interpretation of this lack of correlation
is that low-level adduct formation is not a marker of
liver injury. However, it is also possible that there is low
level liver injury that is not reflected by changes in
transaminases. At this time we cannot make conclusions
regarding the lack of correlation between APAP-CYS
and ALT. The correlation between APAP-CYS and ALT
observed in the overdose cohort was statistically signifi-
cant and similar to other reports [6,14]. For example, a
correlation of 0.84 [14] and 0.73 [6] for ALT were pre-
viously reported in children and adults, respectively,
with APAP overdose. Importantly, the highest concen-
trations of APAP adducts measured in patients were
generally seen in those with severe cases of APAP over-
dose who did not receive timely treatment with NAC.
Conclusion
Our findings support previous studies suggesting APAP-
CYS is a specific marker of acetaminophen exposure,
and that adduct concentrations vary according to the
degree of exposure. Higher concentrations are associated
with liver injury and APAP-CYS was detectable in aceta-
minophen overdose patients. Currently, an absolute
adduct level exceeding 1.1 nmol/mL appears consistent
with acetaminophen toxicity while therapeutic dosing
generally produces concentrations below 0.5 nmol/mL.
Clinical history, including the magnitude of the expo-
sure, the timing of acetylcysteine administration, and
laboratory markers of liver injury should also be taken
into account when interpreting adduct concentrations in
the lower range. A recent publication has described the
use of APAP-CYS to identify occult acetaminophen poi-
soning among patenits with liver failure of unclear etiol-
ogy [15]. It is likely that APAP-CYS will be a useful
diagnostic test in cases in which the history and stan-
dard laboratory testing are not sufficient to establish
acetaminophen as a cause of liver injury
There are other potential applications that should be
investigated in future studies. We had one patient (D =
05) who was stratified as high risk (using the nomo-
gram) but who had low adduct concentrations and who
did not develop liver injury. While this is a single case,
Figure 6 Peak APAP-CYS concentrations plotted by peak ALT
for patients treated within 8 hours of acute overdose, for
patients treated more than 8 hours after acute overdose and
patients treated for repeated supratherapeutic ingestion (RSTI).
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it suggests that a low APAP-CYS in high risk patient
may be a marker that could be used to identify patients
who do not need prolonged therapy. In our small
cohort, we found that APAP-CYS concentrations were
elevated in all patients who developed hepatoxicity
(ALT >1000 IU/L) following repeated ingestions. This
suggests that APAP-CYS may be useful for risk stratifi-
cation following repeated overdose.
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